Building on the first patient case, Dr. Binod Dhakal and Dr. Prerna Mewawalla discuss how recently presented MajesTEC-9 data may influence treatment selection for patients with relapsed/refractory multiple myeloma (RRMM) who experience an early relapse following frontline therapy.
Using a case-based scenario, Dr. Binod Dhakal and Dr. Carol Ann Huff explore treatment decision-making for a fit patient with relapsed/refractory multiple myeloma (RRMM) experiencing first relapse approximately 30 months after autologous stem cell transplantation.
Ajay K. Nooka, MD, MPH, FACP, says the teclistamab-talquetamab combination reduced progression risk by 89% in MonumenTAL-6.
Kay Yoon-Flannery, DO, MPH, FACS, described why the lateral axillary line is her preferred incision site for single-port robotic mastectomy.
Frank McCormick, PhD, FRS, DSc (Hon), outlined the rationale for combining KRAS inhibitors with PI3K and checkpoint inhibitors to improve durability of response.
Frank McCormick, PhD, FRS, DSc (Hon), discussed how RASolute-302 data showing daraxonrasib nearly doubled survival reshaped pancreatic cancer drug development.
Stay tuned for an in-depth discussion on navigating operational workflows and mitigating barriers to access for CAR T-cell therapy in multiple myeloma.
The faculty open the episode by discussing how most patients with hormone receptor-positive, HER2-negative metastatic breast cancer begin treatment with a CDK4/6 inhibitor plus an aromatase inhibitor and many respond well, sometimes for years.
Kay Yoon-Flannery, DO, MPH, FACS, explained how the da Vinci Single Port 3D visualization improves precision vs open or multiport surgery.
James J. Harding, MD, presents the SIERRA study for Team Deep-Dish Pizza, reviewing the phase 3b, single-arm trial of the STRIDE regimen, tremelimumab plus durvalumab, in first-line unresectable hepatocellular carcinoma (HCC) with poor-prognosis features.
Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, predicts operational challenges as CAR T-cell therapy expands to non-oncology indications.
María Teresa Bourlon, MD, MSc, FASCO, discussed why early RadiCal trial closure and adverse effects outweigh secondary survival signals in bone-metastatic RCC.
Dr. Prashant Kapoor reviews the pivotal phase 1/2 LINKER-MM1 study evaluating linvoseltamab, a BCMA × CD3 bispecific antibody, in heavily pretreated patients with relapsed/refractory multiple myeloma (R/R MM).
Dr. Shambavi Richard welcomes viewers to Cancer Network's FACE-OFF, introducing a debate-driven educational program focused on the evolving role of BCMA-targeted therapies in relapsed/refractory multiple myeloma (R/R MM).
María Teresa Bourlon, MD, MSc, FASCO, discussed data showing body composition and muscle loss with lenvatinib/everolimus vs cabozantinib in metastatic ccRCC.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, says equitable access to CAR T-cell therapy depends on partnership, not just center certification.
Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, discussed overcoming insurance barriers to oral AML treatment access.
Dr. Shadman presents a case of a 68-year-old woman with symptomatic CLL requiring treatment.
Dr. Shadman addresses when to switch within the BTKi class versus changing mechanism of action.
Courtney D. DiNardo, MD, MSCE, and Michael R. Savona, MD, shared antiemetic strategies for GI AEs with oral AML regimens.
Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla discuss the growing number of BCMA-directed bispecific antibody options available for patients with relapsed/refractory multiple myeloma (RRMM) and the practical considerations that influence treatment selection.
Dr. Binod Dhakal and Dr. Prerna Mewawalla discuss how evolving dosing strategies are helping improve the real-world use of BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM).
Tiba Al Sagheer, PharmD, BCOP, BCACP, said CAR T-cell expansion signals toxicity risk differently across cilta-cel and ide-cel.
Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, discussed ARC initiative data on venetoclax dose modifications in AML.
Kathryn Eckert, DO, spoke about diversifying breast imaging technology after the Hologic Brevera needle recall.
Herbert Lepor, MD, outlines NYU Langone’s long-term PSA and MRI surveillance protocol following focal cryoablation for prostate cancer.
Paul Oberstein, MD, discusses how RASolute 302 may be the most significant advance in pancreatic cancer treatment in more than a decade.
Differentiating between CRS and IEC-HS remains a challenge in mitigating toxicity associated with cellular therapy, said Tiba Al Sagheer, PharmD, BCOP, BCACP.
Kathryn Eckert, DO, shared how her team communicates with patients and keeps referral guidelines unchanged during the shortage.
The panel discusses ipilimumab dosing and the management of immune-related toxicity with nivolumab plus ipilimumab in advanced hepatocellular carcinoma (HCC).
